Hironobu Yanagie1,2,3, Takashi Fujino4, Masashi Yanagawa5, Toshimitsu Terao6, Takashi Imagawa7, Mitsuteru Fujihara8, Yasuyuki Morishita9, Ryouji Mizumachi10, Yuuji Murata10, Novriana Dewi11, Yuuya Ono8, Ichiro Ikushima12,13, Koji Seguchi14, Masashi Nagata15, Yasumasa Nonaka16, Yoshitaka Furuya17, Tomoyuki Hisa18, Takeshi Nagasaki19, Kazuhiko Arimori20, Tadao Nakashima13, Takumichi Sugihara11, Kazuhiro Kakimi21, Minoru Ono2,22, Jun Nakajima2,23, Masazumi Eriguchi24, Shushi Higashi13,14, Hiroyuki Takahashi25,2. 1. Institute of Engineering Innovation, School of Engineering, The University of Tokyo, Tokyo, Japan; h.yanagie@gmail.com. 2. Cooperative Unit of Medicine and Engineering, The University of Tokyo Hospital, Tokyo, Japan. 3. Research Institute of Healthy Living, Niigata University of Pharmacy and Applied Life Sciences, Niigata, Japan. 4. Department of Pathology, Saitama Medical University International Medical Center, Hidaka, Japan. 5. Veterinary Medical Center, Obihiro University of Agriculture and Veterinary Medicine, Hokkaido, Japan. 6. Department of Pharmaceutical Technology, Otsuka Pharmaceutical Factory, Tokushima, Japan. 7. Department of Chemical Science and Engineering, Graduate School of Engineering, Kobe University, Hyogo, Japan. 8. SPG Techno Ltd. Co., Miyazaki Techno Research Park, Miyazaki, Japan. 9. Department of Human and Molecular Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. 10. Department of Pharmacology, Kumamoto Institute Branch, LSI Medience Ltd. Co., Kumamoto, Japan. 11. Laboratory of Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, Niigata, Japan. 12. Department of Radiology, Miyakonojo Shigun Ishikai Hospital, Miyazaki, Japan. 13. Kyushu Medical Resource Foundation, Miyazaki, Japan. 14. Department of Surgery, Kojin-kai Medical City East Hospital, Miyazaki, Japan. 15. Department of Pharmacy, Medical Hospital, Tokyo Medical and Dental University, Tokyo, Japan. 16. Department of Surgery, Keiai-kai Houyou Hospital, Iwate, Japan. 17. Department of Surgery, Sodegaura Satukidai Hospital, Chiba, Japan. 18. Tokyo Bunkyo Study Center, The Open University of Japan, Tokyo, Japan. 19. Department of Bioengineering, Osaka City University Graduate school of Engineering, Osaka, Japan. 20. Department of Pharmacy, Miyazaki Medical University Hospital, Miyazaki, Japan. 21. Department of Immunotherapeutics, The University of Tokyo Hospital, Tokyo, Japan. 22. Department of Cardiovascular Surgery, The University of Tokyo Hospital, Tokyo, Japan. 23. Department of Thoracic Surgery, The University of Tokyo Hospital, Tokyo, Japan. 24. Department of Surgery, Shin-Yamanote Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan. 25. Institute of Engineering Innovation, School of Engineering, The University of Tokyo, Tokyo, Japan.
Abstract
BACKGROUND/AIM: A mixture of anticancer agents and iodized poppy seed oil (IPSO) has been widely used for intra-arterial chemotherapy of hepatocellular carcinoma. However, the anticancer agents can easily separate from IPSO, so the therapeutic potential is limited. We developed epirubicin-entrapped water-in-oil-in-water emulsion (WOW-Epi) using a double-membrane emulsification technique. MATERIALS AND METHODS: We delivered WOW-Epi through a hepatic arterial injection to VX2 hepatic tumor rabbit model (1.2 mg/kg). RESULTS: VX2 tumor growth was selectively suppressed in the WOW-Epi-treated group compared with the control treated groups. The accumulation of WOW in nearby cancer cells was confirmed via electron-microscopy. Endocytosis seemed to be the mechanism underlying the uptake of WOW. CONCLUSION: WOW-Epi led to tumour growth suppression in vivo. WOW does not cause toxicity to arterial vessels. WOW-Epi will be hopefully used for repeated intra-arterial chemotherapy to HCC patients in the near future. Copyright
BACKGROUND/AIM: A mixture of anticancer agents and iodized poppy seed oil (IPSO) has been widely used for intra-arterial chemotherapy of hepatocellular carcinoma. However, the anticancer agents can easily separate from IPSO, so the therapeutic potential is limited. We developed epirubicin-entrapped water-in-oil-in-water emulsion (WOW-Epi) using a double-membrane emulsification technique. MATERIALS AND METHODS: We delivered WOW-Epi through a hepatic arterial injection to VX2 hepatic tumor rabbit model (1.2 mg/kg). RESULTS: VX2 tumor growth was selectively suppressed in the WOW-Epi-treated group compared with the control treated groups. The accumulation of WOW in nearby cancer cells was confirmed via electron-microscopy. Endocytosis seemed to be the mechanism underlying the uptake of WOW. CONCLUSION:WOW-Epi led to tumour growth suppression in vivo. WOW does not cause toxicity to arterial vessels. WOW-Epi will be hopefully used for repeated intra-arterial chemotherapy to HCC patients in the near future. Copyright
Authors: Y Katagiri; K Mabuchi; T Itakura; K Naora; K Iwamoto; Y Nozu; S Hirai; N Ikeda; T Kawai Journal: Cancer Chemother Pharmacol Date: 1989 Impact factor: 3.333
Authors: H Yanagië; T Tomita; H Kobayashi; Y Fujii; Y Nonaka; Y Saegusa; K Hasumi; M Eriguchi; T Kobayashi; K Ono Journal: Br J Cancer Date: 1997 Impact factor: 7.640